Drug-eluting resorbable scaffolds “among most exciting technologies” in treatment of peripheral arterial disease


A temporary mechanical support with antiproliferative properties might combine two particular treatment qualities to fill a gap in the treatment armamentarium for peripheral arterial disease, both above and below the knee. Ramon Varcoe (Sydney, Australia) moderates a panel with global experts Brian De Rubertis (New York, USA), Andrew Holden (Auckland, New Zealand), Marianne Brodmann (Graz, Vienna) and Michel Bosiers (Bern, Switzerland) to discuss the promise this technology offers in a hostile environment prone to complex lesions, calcification, chronic total occlusions, dissections and recoil, where other technologies, such as “workhorse” angioplasty, drug-coated balloons and drug-eluting stents have yet to prove efficacy and/or long-term durability.

At the CX Live studio, the panellists discuss the mode of action of drug-eluting resorbable scaffolds (DRS), the clinical evidence being generated and share a long-term 10-year case result to illustrate the early experience and promise of this new class of devices, particularly as they offer the option of leaving nothing behind.

The panel updates viewers on several new technologies in this space including the LIFE-BTK randomised controlled trial of the Esprit BTK scaffold (Abbott Vascular), the first-in-man study of the Magnitude sirolimus-eluting bioresorbable scaffold device (R3 Vascular), a pilot study followed by a multicentre randomised trial of the MOTIV bioresorbable scaffold (Reva Medical) and the ongoing first-in-human above-the-knee clinical trial, EFEMORAL I (of the Efemoral vascular scaffold from Efemoral.

This panel discussion is supported by an educational grant from Abbott Vascular.